Click on a field for details on how to access that data via Web API, Excel, or CSV File Download.
| Open Price | |
| High Price | |
| Low Price | |
| Close Price | |
| Change | |
| Percent Change | |
| Volume |
| Avg Daily Volume | 98,982 |
| 52 Week High | $8.32 |
| 52 Week Low | $2.50 |
| Target Price | $18.00 |
| Ticker | XBIT:UW |
| Composite Ticker | XBIT:US |
| Security Name | XBiotech Inc |
| Type | Ordinary Shares |
| Class | XBIT |
| Currency | USD |
| Round Lot Size | 100 |
| Primary | Yes |
| Delisted | No |
| ETF | No |
| Market Category | Common Stock |
| Market Sector | N/A |
| Exchange Symbol | ^USCOMP |
| Exchange Name | US COMPOSITE |
| Exchange City | N/A |
| Exchange Country | UNITED STATES OF AMERICA |
| Exchange Website | N/A |
| FIGI | BBG0081S8DS2 |
| Composite FIGI | BBG0081S8D39 |
| Share Class FIGI | BBG0081S8D48 |
| FIGI Unique ID | EQ0000000040910373 |
| Dividend | $2.10 |
| Dividend Rate | $2.10 |
| Trailing Dividend Yield | 0.00% |
| 5-year Average Dividend Yield | 14.09% |
| Dividend Ex Date | 2021-07-15 |
| Beta | 1.1233 |
| 1-year beta | 1.1149 |
| 3-year beta | 1.1233 |
| 5-year beta | 1.1501 |
| 7-year beta | 0.7724 |
| 10-year beta | 0.796 |
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
